Sali Michela, Clarizio Sandra, Pusceddu Cinzia, Zumbo Antonella, Pecorini Giovanni, Rocca Stefano, Zanetti Stefania, Delogu Giovanni, Fadda Giovanni
Institute of Microbiology, Catholic University of the Sacred Heart, Largo A. Gemelli 8, 00168 Rome, Italy.
Microbes Infect. 2008 May;10(6):605-12. doi: 10.1016/j.micinf.2008.02.012. Epub 2008 Feb 23.
Development of multigenic constructs expressing Mycobacterium tuberculosis (Mtb) antigens may be a strategy to obtain improved DNA vaccines against tuberculosis (TB). Several multigenic constructs expressing two or three Mtb antigens as fusion proteins were developed, both as tPA- and ubiquitin-fusion proteins. To demonstrate proper protein expression and intracellular turnover all multiantigens were tagged with the HA epitope and constructs were used to transfect rhabdomyosarcoma (RD) cells. Antigen expression was demonstrated by immunofluorescence using anti-HA antibodies. C57Bl/6 mice were immunized with selected constructs and protective activity was assessed following aerogenic challenge with Mtb. Several of these constructs induced a significant level of protection in the lung and in the spleen. Immunization with the construct expressing tPA85B-ES6 induced a level of protection that approached that provided by BCG. Immunization with a combination of these constructs induced levels of protection that were not superior to those elicited by a single combination, and immunization with a construct expressing five Mtb antigens could not provide an improved level of protection compared to tPA85B-ES6. We conclude that the activity of a DNA vaccine based on tPA85B-ES6 cannot be enhanced by broadening the antigen repertoire with other highly immunogenic secreted Mtb proteins.
开发表达结核分枝杆菌(Mtb)抗原的多基因构建体可能是获得改进的抗结核病(TB)DNA疫苗的一种策略。已开发出几种将两种或三种Mtb抗原作为融合蛋白表达的多基因构建体,包括组织型纤溶酶原激活物(tPA)融合蛋白和泛素融合蛋白。为了证明蛋白质的正确表达和细胞内周转,所有多抗原均用HA表位进行标记,并使用构建体转染横纹肌肉瘤(RD)细胞。使用抗HA抗体通过免疫荧光证明抗原表达。用选定的构建体免疫C57Bl/6小鼠,并在用Mtb进行气溶胶攻击后评估保护活性。其中几种构建体在肺和脾脏中诱导了显著水平的保护作用。用表达tPA85B-ES6的构建体免疫诱导的保护水平接近卡介苗(BCG)提供的保护水平。用这些构建体的组合进行免疫诱导的保护水平并不优于单一组合诱导的保护水平,并且与tPA85B-ES6相比,用表达五种Mtb抗原的构建体进行免疫不能提供更高水平的保护。我们得出结论,基于tPA85B-ES6的DNA疫苗的活性不能通过用其他高度免疫原性的分泌型Mtb蛋白扩大抗原库来增强。